share_log

Illumina | 8-K: Current report

Illumina | 8-K: Current report

Illumina | 8-K：重大事件
美股sec公告 ·  05/02 16:24
Moomoo AI 已提取核心信息
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, reported its financial results for the first quarter of fiscal year 2024 on May 2, 2024. The company announced a slight decrease in core revenue, with $1.06 billion for Q1 2024, a 2% drop from Q1 2023. Despite the decline, Illumina's non-GAAP operating margin improved to 20.6% for the quarter. The company also reported a GAAP diluted loss per share of ($0.79) for Q1 2024, compared to GAAP diluted earnings per share of $0.02 for Q1 2023, and non-GAAP diluted earnings per share of $0.09 for Q1 2024, up from $0.08 in Q1 2023. Illumina is reiterating its fiscal year 2024 guidance, expecting approximately flat Core Illumina revenue compared to 2023 and a non-GAAP operating margin of about 20%. Additionally, Illumina is on track to divest GRAIL, a healthcare company focused on early cancer detection, by the end of Q2 2024, following the European Commission's approval of its divestment plan in April. The divestment plan may require Illumina to provide GRAIL with approximately $1 billion in funding if a capital markets transaction is pursued.
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, reported its financial results for the first quarter of fiscal year 2024 on May 2, 2024. The company announced a slight decrease in core revenue, with $1.06 billion for Q1 2024, a 2% drop from Q1 2023. Despite the decline, Illumina's non-GAAP operating margin improved to 20.6% for the quarter. The company also reported a GAAP diluted loss per share of ($0.79) for Q1 2024, compared to GAAP diluted earnings per share of $0.02 for Q1 2023, and non-GAAP diluted earnings per share of $0.09 for Q1 2024, up from $0.08 in Q1 2023. Illumina is reiterating its fiscal year 2024 guidance, expecting approximately flat Core Illumina revenue compared to 2023 and a non-GAAP operating margin of about 20%. Additionally, Illumina is on track to divest GRAIL, a healthcare company focused on early cancer detection, by the end of Q2 2024, following the European Commission's approval of its divestment plan in April. The divestment plan may require Illumina to provide GRAIL with approximately $1 billion in funding if a capital markets transaction is pursued.
DNA测序和基于阵列的技术领域的全球领导者Illumina, Inc. 于2024年5月2日公布了2024财年第一季度的财务业绩。该公司宣布核心收入略有下降，2024年第一季度为10.6亿美元，较2023年第一季度下降2％。尽管有所下降，但Illumina本季度的非公认会计准则营业利润率仍提高至20.6％。该公司还报告称，2024年第一季度GAAP摊薄后每股亏损为（0.79美元），而2023年第一季度的GAAP摊薄后每股收益为0.02美元，2024年第一季度非公认会计准则摊薄后每股收益为0.09美元，高于2023年第一季度的0.08美元。Illumina重申了其2024财年的指导方针，预计Co...展开全部
DNA测序和基于阵列的技术领域的全球领导者Illumina, Inc. 于2024年5月2日公布了2024财年第一季度的财务业绩。该公司宣布核心收入略有下降，2024年第一季度为10.6亿美元，较2023年第一季度下降2％。尽管有所下降，但Illumina本季度的非公认会计准则营业利润率仍提高至20.6％。该公司还报告称，2024年第一季度GAAP摊薄后每股亏损为（0.79美元），而2023年第一季度的GAAP摊薄后每股收益为0.02美元，2024年第一季度非公认会计准则摊薄后每股收益为0.09美元，高于2023年第一季度的0.08美元。Illumina重申了其2024财年的指导方针，预计Core Illumina的收入与2023年相比基本持平，非公认会计准则的营业利润率约为20％。此外，继欧盟委员会于4月批准撤资计划之后，Illumina有望在2024年第二季度末之前剥离专注于癌症早期发现的医疗保健公司GRAIL。如果进行资本市场交易，撤资计划可能要求Illumina向GRAIL提供约10亿美元的资金。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息